Fourth-generation fluoroquinolone widens the choice of antibiotic
Critical review of relevant factors drives fourth-generation fluoroquinolone selection for treatment of ocular infection
Publish date: September 15, 2009
Cheryl Guttman
Cheryl Guttman
The introduction of a new fourth-generation fluoroquinolone for ophthalmic use may prompt an assessment of the pros and cons of the available agents. James P. McCulley, MD, explains his continued preference for moxifloxacin 0.5% (Vigamox, Alcon).